21 research outputs found
Coenzyme Q10 dose-escalation study in hemodialysis patients: safety, tolerability, and effect on oxidative stress.
BackgroundCoenzyme Q10 (CoQ10) supplementation improves mitochondrial coupling of respiration to oxidative phosphorylation, decreases superoxide production in endothelial cells, and may improve functional cardiac capacity in patients with congestive heart failure. There are no studies evaluating the safety, tolerability and efficacy of varying doses of CoQ10 in chronic hemodialysis patients, a population subject to increased oxidative stress.MethodsWe performed a dose escalation study to test the hypothesis that CoQ10 therapy is safe, well-tolerated, and improves biomarkers of oxidative stress in patients receiving hemodialysis therapy. Plasma concentrations of F2-isoprostanes and isofurans were measured to assess systemic oxidative stress and plasma CoQ10 concentrations were measured to determine dose, concentration and response relationships.ResultsFifteen of the 20 subjects completed the entire dose escalation sequence. Mean CoQ10 levels increased in a linear fashion from 704 ± 286 ng/mL at baseline to 4033 ± 1637 ng/mL, and plasma isofuran concentrations decreased from 141 ± 67.5 pg/mL at baseline to 72.2 ± 37.5 pg/mL at the completion of the study (P = 0.003 vs. baseline and P < 0.001 for the effect of dose escalation on isofurans). Plasma F2-isoprostane concentrations did not change during the study.ConclusionsCoQ10 supplementation at doses as high as 1800 mg per day was safe in all subjects and well-tolerated in most. Short-term daily CoQ10 supplementation decreased plasma isofuran concentrations in a dose dependent manner. CoQ10 supplementation may improve mitochondrial function and decrease oxidative stress in patients receiving hemodialysis.Trial registrationThis clinical trial was registered on clinicaltrials.gov [NCT00908297] on May 21, 2009
Serum Amyloid A Impairs the Antiinflammatory Properties of HDL
HDL from healthy humans and lean mice inhibits palmitate-induced adipocyte inflammation; however, the effect of the inflammatory state on the functional properties of HDL on adipocytes is unknown. Here, we found that HDL from mice injected with AgNO3 fails to inhibit palmitate-induced inflammation and reduces cholesterol efflux from 3T3-L1 adipocytes. Moreover, HDL isolated from obese mice with moderate inflammation and humans with systemic lupus erythematosus had similar effects. Since serum amyloid A (SAA) concentrations in HDL increase with inflammation, we investigated whether elevated SAA is a causal factor in HDL dysfunction. HDL from AgNO3-injected mice lacking Saa1.1 and Saa2.1 exhibited a partial restoration of antiinflammatory and cholesterol efflux properties in adipocytes. Conversely, incorporation of SAA into HDL preparations reduced antiinflammatory properties but not to the same extent as HDL from AgNO3-injected mice. SAA-enriched HDL colocalized with cell surface–associated extracellular matrix (ECM) of adipocytes, suggesting impaired access to the plasma membrane. Enzymatic digestion of proteoglycans in the ECM restored the ability of SAA-containing HDL to inhibit palmitate-induced inflammation and cholesterol efflux. Collectively, these findings indicate that inflammation results in a loss of the antiinflammatory properties of HDL on adipocytes, which appears to partially result from the SAA component of HDL binding to cell-surface proteoglycans, thereby preventing access of HDL to the plasma membrane
A Cluster of Proteins Implicated in Kidney Disease Is Increased in High-Density Lipoprotein Isolated from Hemodialysis Subjects
Exploring the relationship of brown adipose tissue to bone microarchitecture using 7T MRI and micro-CT
Background. Brown adipose tissue (BAT) is
involved both in energy production and bone
metabolism. The purpose of this study was to analyze
the relationship between BAT and microarchitecture at
cancellous and cortical bone using Kunming mice and
the methods of 7T magnetic resonance imaging (MRI)
combined with micro-CT.
Methods. Twenty-four female Kunming mice were
examined by 7T MRI and measured T2* relaxation time
on the deep and superficial interscapular BAT (iBAT)
and subcutaneous white adipose tissue (sWAT).
Cancellous bone microarchitecture of the distal femur
and cortical bone of the middle femur were examined by
micro-CT. A paired t-test was used to analyze the
differences in T2* values between iBAT and sWAT. The
correlation between BAT T2* values and bone
microstructure parameters were analyzed using
Pearson’s correlation.
Results. T2* values of the deep and superficial iBAT
(6.36±3.31 ms and 6.23±2.61 ms) were significantly
shorter than those of sWAT (16.30±3.05 ms, tdeep iBAT=-
10.816), tsuperficial iBAT=-12.276, p<0.01). Deep iBAT
T2* values were significantly and negatively correlated
with bone volume, cancellous thickness, and bone
thickness (Th) and trabecular thickness (Tb.Th) of the
cancellous bone of femur. Deep iBAT T2* values were
significantly and positively correlated with the structural
model index of cancellous bone of femur. Deep iBAT
T2* values were significantly and negatively correlated
with bone mineral density of the cortical bone of femur.
Conclusions. MRI can distinguish the two adipose
tissues from each other. T2* values of BAT were lower
than WAT on MRI. BAT related bone remodeling was
more correlated with the microstructure of cancellous
bone than that of cortical bone
Recommended from our members
A Cluster of Proteins Implicated in Kidney Disease Is Increased in High-Density Lipoprotein Isolated from Hemodialysis Subjects
Cardiovascular disease is the leading cause of death in end-stage renal disease (ESRD) patients treated with hemodialysis. An important contributor might be a decline in the cardioprotective effects of high-density lipoprotein (HDL). One important factor affecting HDL's cardioprotective properties may involve the alterations of protein composition in HDL. In the current study, we used complementary proteomics approaches to detect and quantify relative levels of proteins in HDL isolated from control and ESRD subjects. Shotgun proteomics analysis of HDL isolated from 20 control and 40 ESRD subjects identified 63 proteins in HDL. Targeted quantitative proteomics by isotope-dilution selective reaction monitoring revealed that 22 proteins were significantly enriched and 6 proteins were significantly decreased in ESRD patients. Strikingly, six proteins implicated in renal disease, including B2M, CST3, and PTGDS, were markedly increased in HDL of uremic subjects. Moreover, several of these proteins (SAA1, apoC-III, PON1, etc.) have been associated with atherosclerosis. Our observations indicate that the HDL proteome is extensively remodeled in uremic subjects. Alterations of the protein cargo of HDL might impact HDL's proposed cardioprotective properties. Quantifying proteins in HDL may be useful in the assessment of cardiovascular risk in patients with ESRD and in assessing response to therapeutic interventions
Quantifying HDL proteins by mass spectrometry: how many proteins are there and what are their functions?
A Cluster of Proteins Implicated in Kidney Disease Is Increased in High-Density Lipoprotein Isolated from Hemodialysis Subjects
Cardiovascular
disease is the leading cause of death in end-stage
renal disease (ESRD) patients treated with hemodialysis. An important
contributor might be a decline in the cardioprotective effects of
high-density lipoprotein (HDL). One important factor affecting HDL’s
cardioprotective properties may involve the alterations of protein
composition in HDL. In the current study, we used complementary proteomics
approaches to detect and quantify relative levels of proteins in HDL
isolated from control and ESRD subjects. Shotgun proteomics analysis
of HDL isolated from 20 control and 40 ESRD subjects identified 63
proteins in HDL. Targeted quantitative proteomics by isotope-dilution
selective reaction monitoring revealed that 22 proteins were significantly
enriched and 6 proteins were significantly decreased in ESRD patients.
Strikingly, six proteins implicated in renal disease, including B2M,
CST3, and PTGDS, were markedly increased in HDL of uremic subjects.
Moreover, several of these proteins (SAA1, apoC-III, PON1, etc.) have
been associated with atherosclerosis. Our observations indicate that
the HDL proteome is extensively remodeled in uremic subjects. Alterations
of the protein cargo of HDL might impact HDL’s proposed cardioprotective
properties. Quantifying proteins in HDL may be useful in the assessment
of cardiovascular risk in patients with ESRD and in assessing response
to therapeutic interventions
A Cluster of Proteins Implicated in Kidney Disease Is Increased in High-Density Lipoprotein Isolated from Hemodialysis Subjects
Cardiovascular
disease is the leading cause of death in end-stage
renal disease (ESRD) patients treated with hemodialysis. An important
contributor might be a decline in the cardioprotective effects of
high-density lipoprotein (HDL). One important factor affecting HDL’s
cardioprotective properties may involve the alterations of protein
composition in HDL. In the current study, we used complementary proteomics
approaches to detect and quantify relative levels of proteins in HDL
isolated from control and ESRD subjects. Shotgun proteomics analysis
of HDL isolated from 20 control and 40 ESRD subjects identified 63
proteins in HDL. Targeted quantitative proteomics by isotope-dilution
selective reaction monitoring revealed that 22 proteins were significantly
enriched and 6 proteins were significantly decreased in ESRD patients.
Strikingly, six proteins implicated in renal disease, including B2M,
CST3, and PTGDS, were markedly increased in HDL of uremic subjects.
Moreover, several of these proteins (SAA1, apoC-III, PON1, etc.) have
been associated with atherosclerosis. Our observations indicate that
the HDL proteome is extensively remodeled in uremic subjects. Alterations
of the protein cargo of HDL might impact HDL’s proposed cardioprotective
properties. Quantifying proteins in HDL may be useful in the assessment
of cardiovascular risk in patients with ESRD and in assessing response
to therapeutic interventions